Cytokinetics(US:CYTK) Prnewswire·2025-09-25 00:37Core Viewpoint - A class action lawsuit has been filed against Cytokinetics, Inc. for allegedly misleading investors regarding the New Drug Application (NDA) submission timeline for aficamten, which may have caused financial losses to shareholders [2]. Group 1: Allegations and Legal Proceedings - The lawsuit claims that Cytokinetics made materially false statements about the expected approval timeline for aficamten, indicating that approval from the U.S. FDA was anticipated in the second half of 2025, based on a PDUFA date of September 26, 2025 [2]. - The company allegedly failed to disclose significant risks related to its inability to submit a Risk Evaluation and Mitigation Strategy, which could delay the regulatory process [2]. - Shareholders experienced financial losses when the truth about the NDA submission was revealed [2]. Group 2: Participation and Representation - Shareholders may be eligible to participate in the class action and those wishing to serve as lead plaintiff must submit their papers by November 17, 2025 [3]. - The lead plaintiff will represent other class members in directing the litigation, but participation is not required to be eligible for recovery [3]. Group 3: Firm Background - Robbins LLP is a recognized leader in shareholder rights litigation, dedicated to helping shareholders recover losses and improve corporate governance since 2002 [4].